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INTRODUCTION 
 
 
 Organophosphorus compounds are chemical agents in widespread use throughout the 
world mainly in agriculture. They comprise the ester, amide or thiol    derivatives of 
phosphoric acid and are most commonly used as pesticides in commercial agriculture. 
 
 There are no rules and regulations governing the purchase of these products, and they 
are therefore readily available "over the counter", despite them being a major cause of 
morbidity and mortality. Poisoning occurs either by a suicidal attempt or by an accidental 
exposure of the compound during spraying. 
  
 Estimates from the WHO indicate that each year, 1 million accidental poisonings and 
2 million suicide attempts involving pesticidesoccur world over. Early diagnosis and 
prompt treatment is required to save the patient's life1. The incidence of intentional 
organophosphate related human exposure is underestimated1.3  
Large proportion  of  patients present to the ICU with acute suicidal 15,16  attempt and male 
predominance.                                         
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REVIEW OF LITERATURE 
 
Organophosphates were first synthesised in the early 1800 s. when Lassaigne reacted 
alcohol with phosphoric acid.  A chemist at Bayer AG Germany investigated the use of       
organophosphates as insecticide  during World War II in 1941, Organophosphates were 
reintroduced world wide as pesticides 45.  
 
Exposure to organophosphates is also possible via intentional or unintentional 
contamination of food sources. Although no clinical effects of chronic low level exposure 
from  food sources have been shown, advancement in risk assessment and preparedness are 
on going 46.  
 
Organophosphates may affect children or other at risk populations differently. The 
increased susceptibility has not been elucidated but may involve delayed or persistant 
effects. More work in this area is under way 47.   
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INCIDENCE AND PREVALANCE 
 
Most cases occur in the developing world as a result of occupational or deliberate exposure 
to  organophosphate pesticides. Organophosphates seem to be the most important cause of 
death from self poisoning world wide.  Case mortality rate in the developing world is more 
than 20% 49.  
 
A retrospective study of  organophosphate poisoned patients by Livetal found a direct 
correlation between severity of poisoning and mortality and the presence of pretreatment 
metabolic and respiratory acidosis 50. 
 
CLASSIFICATION 
 
  There are classified according to their toxicity and clinical use: 
1. Highly toxic - (e.g. parathion).  
2. Intermediately toxic - (e.g clorpyriphos, trichlorfon) 
3. Low toxicity - (e.g. diazinon, malathion, dichlorvos).  
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MECHANISM OF ACTION OF ORGANOPHOSPHORUS COMPOUNDS 
Acetylcholine is the neurotransmitter released at all postganglionic parasympathetic 
nerve endings and at the synapses of both sympathetic and parasympathetic ganglia. It is 
also released at the skeletal muscle myoneural junction and serves as the neurotransmitter in 
the CNS 18.  It is hydrolyzed by acetylcholinesterase into two fragments: acetic acid and 
choline. 
Acetylcholinesterase is present in two forms: True acetylcholinesterase which is 
found primarily in the tissues and erythrocytes, and pseudocholinesterase which is found in 
the serum and liver 19.   
Accumulation of acetylcholine causes overstimulation of both muscarinic and 
nicotinic receptors, and subsequently disrupts the transmission of nerve impulses in both the 
peripheral and central nervous system.  
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PHARMACOKINETICS 
 
Most organophosphates are highly lipid soluble compounds and are well absorbed 
from intact skin, oral mucous membranes, conjunctiva and the gastrointestinal and 
respiratory tracts. They are rapidly redistributed to all body tissues. The highest 
concentrations are found in the liver and kidneys. As they are highly lipid soluble they 
easily cross the blood brain barrier and therefore produce potent effects on the   central 
nervous systeml 
 
Metabolism occurs principally by oxidation in the liver by conjugation and esterase 
hydrolysis producing a half-life of minutes to hours. The oxidative metabolites of malathion 
and parathion are active forms. Elimination of organophosphorus compounds occur via 
urine, bile and faeces.  
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CLINICAL FEATURES OF ORGANOPHOSPHORUS POISONING 
 
Following exposure toxic features are obvious within 30 minutes to 3 hours. They 
may be delayed in some cases depending on the rate and amount of systemic absorption. 
 
The clinical symptoms and signs are non-specific and depend on the quantity of the 
specific agent and the route of entry. Most fatalities occur within 24 hours and those who 
recover do so within 10 days.  
The clinical features can be broadly classified as secondary to the                    
a. Muscurinic effects  
b. Nicotinic effects and    
c. Central receptor stimulation5
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TABLE 1 : SYMPTOMS AND SIGNS OF ORGANOPHOSPHORUS POISONING 
MUSCARINIC 
RECEPTORS 
NICOTINIC 
RECEPTORS 
CENTRAL 
RECEPTORS 
 
CARDIOVASCULAR 
o Bradycardia 
o Hypotension 
RESPIRATORY 
o Rhinorrhoea 
o Bronchorrhoea 
o Bronchospasm 
o Cough 
GASTROINTESTINAL 
o Nausea/vomiting 
o Increased salivation 
o Abdominal cramps 
o Diarrhoea 
 
 
CARDIOVASCULAR 
o Tachycardia 
o Hypertension 
MUSCULOSKELETAL 
o Weakness  
o Fasciculations  
o Cramps 
o Paralysis 
EYES 
o Blurred vision 
o Miosis 
o Increased 
lacrimation 
 
 
GENERAL EFFECTS 
o Anxiety  
o Ataxia 
o Insomnia 
o Convulsions 
o Tremors 
o Coma 
o Respiratory 
depression  
 
o Circulatory 
collapse 
GLANDS 
o Excessive 
salivation 
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CARDIAC MANIFESTATIONS 
 
The extent ,frequency and pathogenesis of the cardiac toxicity from these compounds 
are not clearly defined.  The commonest cardiac manifestations are hypotension (with 
warm, dilated peripheries), and bradycardia. Electrocardiographic manifestations include 
prolonged Q-Tc intervals, elevation of the ST segment, inverted T waves and a prolonged 
PR interval.QT prolongation has been found in a higher incidence of respiratory failure and 
mortality39. 
  Three phases of cardiac toxicity following organophosphate poisoning have been 
 described: 
o Phase I: A brief period of increased sympathetic tone 
 
o Phase II: A prolonged period of parasympathetic activity including AV node 
blockade 
o Phase III: Q-T prolongation followed by torsade de pointes, ventricular 
tachycardia and ventricular fibrillation. 
However, according to a recent report the mortality rate has declined considerably 
following intensive management5.  
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 Although bradycardia is thought to dominate in the early cholinergic phase of the 
poisoning sinus tachycardia was more frequent in our study. Similar observations have been 
made by others 16.  
  
The mechanism of cardiac toxicity is unclear and the following have all been 
postulated: 
o A direct toxic effect on the myocardium 
 
o Over activity of cholinergic or nicotinic receptors causing hemodynamic 
alteration. 
 
o Hypoxia 
o Acidosis 
o Electrolyte abnormalities 
o High dose atropine therapy. 
One case of organophosphate – parathion poisoning in a farmer with suicidal attempt 
developed myocardial infarction and succumbed has been described by Yagneshetal 51. 
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RESPIRATORY MANIFESTATIONS 
 
Respiratory manifestations of acute organophosphorus poisoning include 
bronchorrhoea, rhinorrhoea, bronchospasm and laryngeal spasm - due to muscarinic effects. 
Nicotinic effects lead to weakness and subsequent paralysis of respiratory and 
oropharyngeal muscles which may require mechanical ventilation. Central neurological 
depression may lead to respiratory arrest  due to cholinergic stimulation. Acute respiratory 
failure is reported  in 33% of patients with acute poisoning 20.     
 
GASTROINTESTINAL SYMPTOMS 
Vomiting, diarrhea and abdominal cramps are the first to occur after oral ingestion of 
an organophosphorus compound .Acute pancreatitis 21,22 has been reported.Patients may 
have hypo or hyperglycemia.23 
Acute haemorrhagic pancreatitis has been reported a complication of organophosphate 
poisoning.  
A high index of suspicion has to be there to diagnose the condition early and treat 
accordingly52. 
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NEUROLOGICAL MANIFESTATIONS 
 
Three different types of paralysis are recognized based largely on the time of occurrence 
and their differing pathophysiology: 
• Type I paralysis or acute paralysis 
• Type II paralysis or Intermediate syndrome 
• Type III paralysis or Organophosphate- induced delayed polyneuropathy 
 
TYPE I PARALYSIS OR ACUTE PARALYSIS 
This is seen during the initial cholinergic phase. There is persistent depolarization at 
the neuromuscular junction. Clinical features include muscle cramps, fasciculations, 
twitching and weakness. Patients may require ventilatory support due to the weakness of the 
respiratory muscles leading to respiratory depression and arrest. Acute paralysis responds to 
atropine24. 
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TYPE II PARALYSIS OR INTERMEDIATE SYNDROME 
First described in 1974 by Wadia et al14 as type II paralysis and subsequently termed 
"The Intermediate Syndrome" by Senanayake. Since then there  has been numerous reports  
of this syndrome. 24,26,27,28,29 The incidence of this syndrome is between   8%  and  
49%.28,29,30 This develops 24-96 hours after the poisoning. The cardinal feature of this 
syndrome is muscle weakness affecting the proximal limb muscles and neck flexors. The 
cranial nerves supplying the extra-ocular muscles are mostly involved. This phase persist 
for 4-18 days. Nerve conduction shows axonal neuropathy 31.Studies from CMC Vellore 
have shown significant elevation of muscle enzymes.32 
 
TYPE III PARALYSIS OR ORGANOPHOSPHATE- INDUCED 
DELAYED POLYNEUROPATHY  
    Type III paralysis is a sensory motor distal neuropathy that usually occurs after 
ingestion of large doses of organophosphorus compounds9-11 This presents as weakness and 
ataxia following a latent period of 2-4 weeks. Initial stimulation causes excitatory 
fasciculation, which then progresses to an inhibitory paralysis. The cardinal symptoms are 
distal weakness of the hands and feet .Neuro psychiatric manifestations have been 
reported.33 Delayed CNS signs include tremor, anxiety and coma. Cogwheel tremors, 
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choreoathetosis 34 gullian barre syndrome, 35sphincter involvement,36 bilateral recurrent 
larymgeal nerve paralysis 37and ototoxicity 38has been reported. Recovery occurs in 6-12 
months. 
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DIAGNOSIS 
 
Diagnosis of organophosphorus poisoning requires a high index of suspicion. The 
history of exposure may be denied by patients who have attempted suicide, or unavailable 
in unconscious patients. Signs of poisoning include the pungent garlic- like odour of 
organophosphorus in breath and vomitus, miosis, bradycardia and muscle fasciculations. 
Some patients may present with the nicotinic effects of tachycardia, hypertension and 
mydiasis (rather that the anticipated bradycardia and hypotension). 
 
Treatment is initiated immediately, without waiting for blood investigations.    Both 
true and pseudocholinesterase levels have to be estimated to assess poisoning   True 
cholinesterase levels correlate with severity of the poisoning, pseudocholinesterase levels 
do not 40. A 25% or more of the depression of the RBC cholinesterase is taken as an 
indicator of poisoning 19.  
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The level of cholinesterase activity is relative and based on population estimates.  
Neonates and infants have baseline levels that are lower than adults.  The diagnosis is 
confirmed by observing a progressive increase in cholinesterase values till the values 
plateau over time.  
 
Falsely depressed levels of RBC cholinesterase can be found in pernicious anemia, 
haemoglobinopathies, use of antimalarial drugs and oxalated blood tubes. 
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MANAGEMENT OF ORGANOPHOSPHORUS COMPOUNDS 
POISONING 
 
• Skin decontamination 
• Airway protection if indicated  
• Gastric lavage  
• Activated charcoal 0.5-1gm/kg every 4hr  
• Anticholinesterase: Atropine/glycopyrrolate  
• Cholinesterase reactivator: Pralidoxine  
• Ventilatory support  
• Inotropic support  
• Feeding-enteral/parental  
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MANAGEMENT 
DECONTAMINATION 
 
Patient should be removed from the site of exposure and their clothes removed. 
Patient's body should then be thoroughly washed with soap and water to prevent further 
absorption from the skin. Gastric lavage is done.  In unconscious patients the airway needs 
to be protected. Patient should receive activated charcoal 0.5-1 gm/ kg every four hours to 
reduce absorption in the gastrointestinal tract. Adverse effects of activated charcoal include 
aspiration pneumonia, vomiting, diarrhea, constipation, ileus and reduced absorption of oral 
medication 53, 54 & 55.   Lavage is preferred to enforced emesis as this may precipitate 
seizures. Recent study has shown the addition of serotonin adipinate resulted in shortening 
of the cholinergic phase and a 3.5% reduction in the mortality 41. 
AIRWAY AND RESPIRATION 
 
The airway should be secured and adequate oxygenation ensured. Careful observation of 
the respiratory status is required as these patients are prone to develop respiratory failure 
during both the acute phase and during intermediate syndrome. The following should be 
monitored on a regular basis to assess the patient's respiratory status: 
• Respiratory rate 
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• Tidal volume/ vital capacity 
• Neck muscle weakness 
• Ocular muscle involvement eg. diplopia 
• Arterial blood gas analysis 
CARDIAC MONITORING 
 
As mentioned earlier, a wide range of cardiac manifestations can occur and careful 
haemodynamic and electrocardiac monitoring should be undertaken in all patients. It should 
be remembered that hypoxaemia, metabolic and electrolyte abnormalities can all contribute 
to cardiac arrhythmias. Some arrhythmias may require cardiac pacing.   
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ATROPINE.  
Administration of anticholinergics is still the mainstay of treatment, and should be 
started as soon as the airway is secured. Starting dose of atropine is 2mg IV bolus. 
Subsequent doses of 2-5mg every 5-15 minutes should be administered until atropinization 
is achieved. Signs of adequate atropinization include an increased heart rate (>100 
beats/min.), moderately dilated pupils, a reduction in bowel sounds, a dry mouth and a 
decrease in bronchial secretions. The dose of atropine required is maximal on day 1 and 
tends to decrease over the next few days. Atropine does not reverse the skeletal muscle 
effects. 
Excessive treatment with atropine results in toxicity characterised by confusion and 
tachycardia 56.    
GLYCOPYROLATE 
Some studies have shown that glycopyrrolate is equally effective, with fewer central 
nervous system side effects and a better control of secretions12. 
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CHOLINESTERASE REACTIVATOR 
 
Oximes are nucleophilic agents that re-activate the phosphorylated acetylcholinesterase by 
binding to the organophosphorus molecule. Obidoxime is the most potent agent with some 
organophosphorus compounds and HI6 against  42 others. Pralidoxime is less potent.42,43,44   
Pralidoxime has three main actions: 
• A direct action converting the organophosphate to a harmless compound. 
• A transient reaction protecting the enzyme from further inhibition. 
• Reactivation of the inhibited alkyl phosphorylated enzyme to free the active unit (if 
given early enough) 
Pralidoxime should be started as early as possible to prevent permanent binding of the 
organophosphate to acetylcholinesterase. Once this has occurred, receptor regeneration is 
required to allow recovery. Pralidoxime should be continued until adequate spontaneous 
ventilation is achieved by the patient. The effective plasma concentration is 4mg/litre and 
the patient should show signs of improvement 10- 40 minutes after its administration. 
Plasma and pseudocholinesterase levels should ideally be monitored during treatment.  
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PREVENTION 
 
Improved regulation of the availability of pesticides, strict regulation of vendors, and 
modifications in packaging of pesticides may all help reduce the use of organophosphates as 
poisons. Adequate provision of information to the public, regular training of health care 
providers, better availability of drugs and antidotes and the establishment of poison 
information centres will facilitate in reducing the morbidity and mortality related to 
organophosphorus poisoning. Insecticides should be kept out of reach of children, to 
prevent accidental poisoning. During agricultural spraying, proper precautions should be 
taken to prevent inhalation and accidental ingestion of the substance. 
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OBJECTIVES 
 
 To analyze the patients with acute organophosphate poisoning with reference to  
o ECG changes.  
o  Systemic manifestations. 
o Relationship to the nature of compound.  
o Outcome 
 
  
 
MATERIALS & METHODS 
 
 Clinical parameters, CBC, Blood Sugar, Serum Urea, Creatinine, Serum NA+, Serum 
K+, LFT, ABG, ECG, Gastric aspirate analysis and Serum Cholinesterase.   
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BRIEF PROCEDURE 
 All patients admitted with ingestion of Organophosphorus compound was studied. 
The study was carried out over a 5 month period from June 2010.   A detailed history was 
obtained and patients were subjected to thorough physical examination and ECG 
monitoring was done. Results of biochemical investigations including serum electrolytes, 
ECG was monitored. 
 
INCLUSION CRITERIA 
 Patients admitted to the toxicology ward with ingestion of organophosporus  
compound poison. 
 
 
EXCLUSION CRITERIA 
1. Patients with history of cardiovascular disease. 
2. Patients on Cardiac drugs 
3. Patients with chronic renal failure.  
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 RESULTS 
 
 
Epidemiological pattern of Organ phosphorus compound poisoning in poison centre, 
Government General Hospital. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organophosphate poisoning cases account for 53 % of the  
Total poison cases admitted. 
Sl.No. Cases No of patients  
1. Total 255 
2. Organophosphate 135 
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Majority of the patients of Organophosphate poisoning were Referrals 
Sl.No. Referral Frequency Percentage 
1. Referred 108 80 % 
2. Direct 27 20 % 
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AGE PATTERN OF POISONING 
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Majority of the patients are in the age group 21–30 
Accounting for 59 % 
Sl.No. Age Frequency Percentage 
1. < 20 18 13.33 % 
2. 21 – 30 59 43.70% 
3. 31 – 40 26 19.25 % 
4. 41 – 50 16 11.85 % 
5. > 50 16 11.85 % 
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AGE DISTRIBUTION AND MORTALITY 
 
 
 
 
 
  
 
 
 
                                           
 
 
 
 
 
 
 Percentage of death was noted to be increased in the extremes of age groups. 22.2% 
at <20 yrs and 31.12% at >50 yrs.   
Sl.No. Age Frequency Death Percentage 
1. < 20 18 4 22.20 % 
2. 21 – 30 59 10 16.94  % 
3. 31 – 40 26 4 15 .38    
4. 41 – 50 16 1 6.25  % 
5.  > 50 16 5 31.125%  
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Incidence of Organophosphate poisoning is more among Males. 
Sl.No. Sex Frequency Percentage 
1. Male 95 70.37 % 
2. Female 43 31.85 % 
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Mortality and Sex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mortality was more among males accounting for  58 .35% of the cases  expired. 
Sl.No. Sex Frequency Percentage 
1. Male 14    58.35% 
2. Female 10        41.6%   
 	
	 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PATIENTS  ON MECHANICAL VENTILATION. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Cases      - 135 
 
Patients on Ventilator   -    35 
 
Percentage of Patients put on Ventilator - 25.32% 
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Total number of patients put on ventilator   –  35 
Death       -  14 
Percentage of Death in patients put on ventilator  - 37.14 % 
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COMPLICATIONS IN PATIENTS PUT ON VENTILATOR 
 
 
 
S.NO. COMPLICATION  NO. OF 
PATIENTS 
PERCENTAGE 
1. Aspiration Pneumonitis 4 11.42 % 
2. Renal failure  4 11.42 % 
3. Cardiac  Failure  3    8.57%  % 
4. Sepsis 3 8.57 % 
5. HIE 2 5.71 % 
6. Respiratory failure   2 5.71 % 
7. Hepatic Failure 1 2.85 % 
8.  Pneumothorax.   1  2.85 % 
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ANALYSIS OF CASES EXPIRED 
 
 
Of the 24 Patients who had expired nature of the organophosphate was identified in 14 
patients. Nature of the compound with regard to morbidity is as follows 
S.No.   Compound Duration 
of stay in 
Hospital 
Complications ECG Changes 
1. Acetate 15 % + 
Chlorpyriphos  
4 Days   
2. Monocrotophos 7 Days Aspiration 
Pneumonitis 
Tachycardia          
T Wave inversion 
3. Monocrotophos 8 Days Hypothyroidism  
Aspiration 
Pneumonitis 
QT Prolongation 
T wave inversion 
4. Monocrotophos 9 Days HIE / Renal 
Failure 
T wave inversion 
5. Baytex 4 Days Respiratory 
Failure 
 
6. Monocrotophos 15 Days  QT Prolongation 
7. Protenofos 19 Days Sepsis   
8. Quinofos 5 Days Renal Failure Tachycardia  
ST elevation 
9. Paraquat 13 Days Liver Failure, 
Renal Failure 
 
10. Monocrotophos 1 Day  QT Prolongation 
11. Methylparathion 2 Day   Tachycardia 
12. Dimethoat 1 Day Hypotension QT Prolongation 
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ANALYSIS OF CASES EXPIRED 
 
 
Nature of the compound with regard to morbidity is as follows 
S.No.   Compound Duration 
of stay in 
Hospital 
Complications ECG Changes 
13. Unknown   1 Days Hypotension QT Prolongation 
 
14. Unknown 1 Days    
15. Unknown 9 Days ARDS, HIE, 
Sepsis 
T wave inversion 
16. Unknown 3 Days Post cardia arrest, 
HIE 
Bradycardia 
17. Unknown 3 Days Renal Failure, 
shock 
QT Prolongation 
18. Unknown 3 Days Respiratory 
failure, Renal 
Failure, Post 
cardia arrest and 
left 
pneumothorax 
Bradycardia 
19. Methylparathion  3 Days Acute renal 
failure 
ST flattening  
20. Unknown 20 
Minutes 
Post cardia arrest, 
Metabolic 
encephalopathy  
Tachycardia 
21. Unknown 5 Days     
22. Monocrotophos 1 Day  QT Prolongation 
23. Unknown 2 Day    
24. Unknown 1 Day     
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Post mortem was conducted for all the patients. Significant change was noted in one of the 
patients. The postmortem changes observed was 
1. Heart was dilated. 
2. Surface of the heart had petechial haemorrhage. 
3. Thrombus was found in the coronary artery. 
4. Chambers were filled with fluid blood. 
5. Cardiac valves were normal. 
6. The lungs were congested and filled with edematous fluid. 
 
The post mortem changes in the other cases were  
 
1. The heart was normal in size Two cases showed dilated heart.  
2. Petechial haemorrhages was noted all over the surface of the heart 
3. The cardiac valves and the coronaries were normal. 
4. Atheromatous plaques was noted in the root of the aorta in a few cases. 
5. The lungs were congested and filled with edematous fluid. 
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ECG AND CARDIAC   CHANGES IN ORGANOPHOSPHATE POISONING 
S.NO. ECG CHANGES FREQUENCY PERCENTAGE 
1. Normal 59 43.7 % 
2. QT interval 
prolongation 
41 31.1 % 
3. ST/T Wave Changes 35 26.1 % 
4. ST elevation 14 10.4 % 
5. T wave inversions 30 22.3 % 
6. Bradycardia 21 16.2 % 
7. Tachycardia 55 40.5 % 
8. Extrasystole 6 5.4 % 
9. Pulmonary edema 4 2.9 % 
10. Hypotension 8 5.9 % 
11. Arrhythmias 22 16.4 % 
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ECG AND CARDIAC   CHANGES 
 
 

$ 
	%

		

&'!&
!"'!&
('	
 
#&	 
)'	


"'" 
 
No of patients: 
 
 In the observed ECG changes the maximum was Tachycardia followed by QT 
Prolongation.  
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BIOCHEMISTRY VALUES 
 
1. RENAL FUNCTION TEST 
S.NO. VALUES MEAN SD (+/-) 
1. Blood Sugar 
mg/dl 
114.20 74.30 
2. Urea mg/dl 26.94 10.20 
3. Creatinine 0.92 9.45 
4. Sodium 126.52 9.10 
 
2. LIVER FUNCTION TESTS 
 
S.NO. VALUES MEAN SD (+/-) 
1. Bilirubin  0.81 2.30 
2. AST 24.24 20.32 
3. ALT 22.40 16.0 
4. Total Protein g/dl 6.5 0.5 
 
Six patients showed features of renal failure. This was attributed to the hypotension 
following cardiac failure.  One patient had elevated bilirubin with 
features of hepatic failure. 
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DISCUSSION 
 
Comprehensive analysis of 135 cases of acute Organophosphate compound 
poisoning. 
MAGNITUDE OF POISONING 
 
 In our Toxicology unit of Government General Hospital during the study period of 5 
months, the Magnitude of the poisoning was 135 out of the total 335 cases that were 
admitted. This represents a total of 40.2 % of these cases  108 patient were referred from 
nearby Government and few private hospitals belonging to the five districts (Chennai, 
Kancheepuram, Thiruvallur, Vizhupuram and Vellore) 
        
AGE PATTERN 
 In this series of 135 cases, the number of patients below 20 years was 13.33 %, 
between 21 – 30 = 43.70 %, 31 – 40 = 19.25%, 41 – 50 = 11.85 %, > 50 years = 11.85 %. 
The youngest was a patient aged 14 years and the oldest was a patient aged 85 years.  
In a similar study by P. Karki JA Ansari etal of Singapore NA, the majority of 
patients was in 15 – 30 years = 65 % and the mean age group was 26.85 years. The series 
reported in this thesis had the similar pattern of age group affection. This is the most 
productive age groups.  
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The people in this age group are exposed to several pressures in the form of 
emotional conflicts social and economic pressures. This study stresses the importance of 
educative and preventive programs to be targeted in this age group.  
   SEX DISTRIBUTION 
 
 In our poison centre the distribution of Male was 95 (10.37%) and Female was 43 
(30.31%). In a observation of 57 cases by P. Karki JA Ansari et al of Singapore, the 
percentage was 41 % for Male and 59 % for Female. The increased incidence of poisoning 
in our population could be because of easy accessibility to the poison by the Male. The 
majority of them were farmers. 
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OCCUPATION OF PATIENTS 
The majority of the patients were farmers coming from near by villages. 
  
 
                                                                                                       
DEMOGRAPHIC PROFILE 
The majority of the patients were from the lower socioeconomic status being mostly 
farmers by occupation. 
 
 
MAGNITUDE OF SUICIDAL POISONING  
Of the 135 cases 9 were spray poisoning. The rest were suicidal in nature.  
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AGE PATTERN OF MORTALITY 
  
In our study the mortality among the different age groups were        20 = 2.96 %, 21 – 
30 = 7.40 %, 31 – 40 = 2.96 %, 41 – 50 = 0.74 %,        > 50 = 3.70 %. 
 The majority of the mortality was in the age group 21-30 years. The youngest patient 
was aged 14 years and the oldest aged 60 years. In a study by P. Karki JA Ansari et al, the 
major mortality was in the age group   15 – 30 years.  
 
MORTALITY AND SEX 
 
 
 The percentage of mortality was higher in Males – 58 %, when compared to Females 
– 43.1 %. In a similar study by P. Karki JA Ansari et al, the mortality was more among 
Females.  
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ECG CHANGES 
ECG showing ST Elevation in a patient with quinophos poisoning   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ECG showing Bradycardia in a patient with methyl parathionpoisoning’ 
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ECG showing Bradycardia and Tall T Waves in a patient profeno phos poisoning 
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ECG showing Bradycardia and ST segment flattening in a patient with 
Monocrotophos poisoning 
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ECG showing QT prolongation in a patient with Monocrotophos poisoning 
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ECG ABNORMALITIES 
 
 Among the 135 patients significant ECG abnormalities were found in 56.3 %. 43.7 % 
had a normal rate and rhythm, Of the abnormal ECGs 41 (31.1 %) had QT prolongation 14 
(10.4%) had ST elevations, 30 (22.3 %) had T wave inversions, 21 (16.2 %) had 
bradycardia, 55 (40.5 %) had tachycardia, 6 (5.4 %) had exrasystoles, 4 (2.9 %) developed 
pulmonary edema, 8 (15.9%) had hypotension, 22 (16.4 %) had arrhythmias.  
 
 A.M. Saadeh NA Farsakh et al observed cardiac manifestations in     67 %,  ST 
changes 41 %, QT Prolongation 61 %, Bradycardia 28 %, Tachycardia 35 %, Pulmonary 
edema 43 %, arrhythmias 24 %, conduction defects 9 %, hypertension 22 % and 
hypotension 17 %. 
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ECG CHANGES IN CASES EXPIRED 
 
15 of the 24 cases that had expired showed ECG changes accounting for 62.5 %.   Of them 
QT prolongation was observed in 7 cases, Tachycardia in 4 cases, ST elevation in 1 patient, 
bardycardia in 2 patients and T wave inversion in 4 cases.  
 
 
ECG CHANGES AND ITS RELATIONSHIP TO THE NATURE OF THE 
COMPOUND 
 
ECG changes noted were mostly in the highly toxic compounds like monochrotophos, 
Quinophos, Chlorphyriphos, Baytex, Paraquate and Protenophos. Maximum manifestations 
were found in monochrotophos and Chlorphyriphos. 
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RENAL AND LIVER FUNCTION TESTS 
 
 Elevated renal parameters were observed in 7 % and elevated bilirubin and alterations 
in the liver functions was found inone patient. 
 
 
RESPIRATORY COMPLICATIONS 
 Aspiration pneumonitis was observed in 4 patients. Pneumothorax was found in 1 
patient.  
 
 
 
 
MANAGEMENT 
 
 Of the 135 patients, except 2 all the others received stomach and body wash Atropine 
was administered to patients. The average of days of atropine requirement was 2days. P2 
AM infusion was administered to patients 112 patients. Ventilatory support was given to 35 
patients.  
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MORTALITY 
 
• The observed mortality was 17 %. Incidence of ECG abnormalities was 64 % in the 
mortality. The majority of the ECG changes were sinus tachycardia  followed by  
QTprolongation. One patient had significant ST elevations indicating anterolateral 
myocardial infarct.  
 
• 14 of the 24 patients who had died were put on ventilator indicating a percentage of 
58.33 % 
 
• Renal failure was observed in 4 patients 16.6 %. 
 
• Liver failure was observed in one patient. He had multi organ dysfunction in the form 
of Renal failure, Respiratory failure and hypotension.  
 
• Monocrotophos was he compound in which there was a maximum mortality. 
 
 
The mortality in the series observed by P. Karki and JA Ansari et al  was 8.1 %. 
 
The mortality in the series observed by AM Saadeh NA Farsakh et al was 4 % 
The mortality in our population is higher. This could be attributed to the fact the ours    
is a referral centre, receiving seriously ill patients from nearby hospitals.  
 
The case fatality of self poisoning in the developing countries in 10–20 % 
In the western countries, the case fatality is 0.3 % 14 
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CONCLUSION 
 
1. Organophosphorus compound is the most widely used suicidal agent in our 
population. 
 
2. The incidence is highest among farmers. 
 
3. Majority of the poisoning are suicidal. Few are accidental due to spray poisoning. 
 
4. In our observation, incidence is higher in Males than in Females.  
 
5. The highest incidence is found in the age group of 20 – 30 years 
 
6. Death is affected by the nature of the compound consumed. The compounds with 
highest mortality were monochrotophos and Chlorphyrifos. 
 
7. ECG abnormalities are found in the majority of the patients, accounting for a 
percentage of 56.3 %. The major ECG abnormality noted was Tachycardia followed 
by QT prolongation, bradycardia, ST elevations. The mortality was higher in patients 
with significant ECG changes. The incidence of ECG abnormalities was higher in the 
mortality group accounting for 64 %. 
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8. Prognosis is poor in patients presenting with respiratory failure. 
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STRENGTHS AND LIMITATIONS 
1. The majority of the patients were referrals who would have a higher morbidity and 
mortality. 
2. It is a single centre study. 
3. Children are not represented. 
 
 
RECOMMENDATIONS 
  
Organophosphate compound poisoning and mortality is a huge burden on the 
productive population. It is easily available over the counter. Monitoring the sale of these 
compounds may help to limit its availability as a suicidal agent. Steps to educate the 
farmers and provide counseling can be undertaken.  
 

 
References : 
 
1. Sumathi Joshi Bimaya biswas et al. Cardiac manifestations of organophosphate 
poisoning. Singapore medical journal J 2004 Vol 45 (8) 
 
2. Tafuri J,Roberts J.Oraganophosphate poisoning. Ann Emerg Med 1987; 16:193-
202 
 
3. Bardin PG, Van Eeden SF: Organophosphates and carbamate poisoning. Arch 
Intern Med.1994;      154:1433-41 
 
4. Ludomirsky A, Klein H, Sarelli P, Becker B et al. Q-T prolongation and 
polymorphous (Torsade de pointes- ventricular arrhythmias associated with 
organophosphorus insecticide poisoning. Am J Cardiol 1982; 49: 1654-58 
 
5. Senanayake N, Karalliedde L. Pattern of acute poisoning in a  medical unit in 
Central Srilanka J Sci Int 1988; 36 : 101 – 4 
 
6. Wadia RS, Sadagopan C, Amin RB Sardesai HV. Neurological manifestations of 
organophosphorus insecticide poisoning. J Neurol Neurosurg Psychiatry 
1974;37:841-7 
 
7. Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus 
insecticides. An intermediate syndrome N Engl J Med 1987; 316:761-3 
 
8. Moretto A, Lotti M. Poisoning by organophosphorus insecticides and sensory 
neuropathy. J Neurol Neurosurg Psychiatry 1998;64:463-8 
 
 

 
9. Lotti M, Becker CE, Amioff MJ. Organophosphates polyneuropathy: pathogenesis 
and prevention. Neurology 1984;34:658-62 
 
10. Senanayake N. Polyneuropathy following insecticide poisoning; a clinical and 
electrophysiological study. Abstract J Neurol 1985; suppl:203-23  
 
11. Bardin PG, Van Eeden SF. Organophosphorus poisoning: grading the severity and 
comparing treatment between atropine and glycopyyrolate. Crit Care Med 
1990:18:956-60 
 
12. Crit Rev Toxi ed 2007 Mar 37 (3) 279 – 85 Bar Meir C. Sheir O et al.  
 
13. Eddleston M. Critical care 2004 8 : R391 R – 397 
 
14. Eyer P. The role of oximes in the management of organophosphorus pesticide 
poisoning Toxicd Rev. 2003 22 – 166 – 190. 
 
 
15. Ganesvaran T, Subramaniam S, Mhadevan K. Suicide in a northern town of Sri 
Lanka. Acta Psychitrica Scandinavia 1984;69:420-5.  
 
 
16.   Agarwal SB. A clinical, biochemical, neurobehahioral and sociopsychological    
study of 190 patients admitted to hospital as result of acute Oraganophosphorus 
poisoning. Environ Res 1993;62:63-70.       
 
17.  Karalliedde L, Senanayake N. Acute organophosphorus insecticide poisoning in 
Sri Lanka. Forensic   Sci Int 1988;36:97-100.       
  
18.  Tafuri J, Roberts J. Organophosphate poisoning. Ann Emerg Med 1987;16:193-
202.       
 
 
 
19.  Haddad LM. Organophosphates and other insecticides. In: Haddad LM, 
Winchester J, editors, Clinical management of poisoning and drug overdose. New 
York: Saunders; 1990. pp. 1076-87.       
 
20. Tsao TC, Juang Y, Lan R, Shieh W, Lee C. Respiratory failure of acute 
organophosphate and carbamate poisoning, Chest 1990;98:631-6. 
 
21. Martin Rubi JC, Yelamus RF, Laynex BF, et al . Poisoning caused by 
organophosphate insecticides; study of 506 cases (abstract). Rev Clin Exp 
1996;196:145-9.        
22.  Moore PG, James OF. Acute pancreatitis induced by acute organophosphorus 
poisoning. Postgrad Med J 1981;57:600-62.  
 
23. Meller D, Fraser I, Kryger M. Hyperglycaemia in anticholinesterase poisoning. 
Can Med Assoc J 1981;124:745-8.       
 
24. Samal KK, Sahu CS. Organophosphorus poisoning and intermediate syndrome. J 
Assoc Physicians India 1990;38:181-2. 
 
25.  Wadia RS, Sadagopal C, Amin RB, Sardesai HV. Neurological manifestations of 
organophosphorus insecticide poisoning. J Neurol Neurosurg Psychiatry 
1974;37:841-7. 
 
26. De Bleecker H, Vogelaers D, Ceuterick C, et al. Intermediate syndrome due to 
prolonged parathion poisoning. Acta Neurol Scand 1992;86:421-4. 
 
 
 
27. De Bleeker J, Van Den Neucker K, Willems J. The intermediate syndrome in 
organophosphorus poisoning: presentation of a case and review of literature. Clin 
Toxicol 1992;30:321-9.         
 
28. Samuel J, Thomas K, Jeyaseelan L, Peter JV, Cherian AM. Incidence of intermediate 
syndrome in organophosphorus poisoning. Assoc Physicians India 1995;43:321-L3.   
 
29. De Bleecker J, Van Den Neucker K, Colardyn F. Intermediate syndrome in 
organophosphorus poisoning: a prospective study. Crit Care Med 1993;21:1706-11.        
30. He F, Xu H, Qin F, Xu L, Huang J, He X. Intermediate myasthenia syndrome 
following acute organophosphate poisoning-an analysis of 21 cases. Hum Exp 
Toxicol 1998;17:40-5. 
 
31. Peter S, Alexander M, Jeyaseelan L, Cherian AM. Electrophysiological study in 
organophosphorus poisoning [thesis]. In press.        
 
32. John M, Zachariah A, Oommen A. Myopathy associated with organophosphorus 
poisoning. Inpress. 
 
33.  Jamal GA. Neurological syndromes of organophosphorus compounds. Adverse Drug 
React Toxicol Rev 1997;16:133-70 
 
34. Senanayake N, Sanmughanathan PS. Extrapyramidal manifestations complicating 
organophosphorus insecticide poisoning. Hum Exp Toxicol 1995;14:600-4.         
 
35. Adlakha A, Philip PJ, Dhar KL. Guillain Barre Syndrome sequela of 
organophosphorus poisoning. Assoc Physicians India 1987;35:665-6.       
 
 
  
36. Patil RK ,Bansal SK, Sehgal VK, Chander B. Shincteric involvement in 
organophosphorus poisoning. Assoc Physicians India 1991;39:492-3.        
 
37. De Silva HJ, Sanmuganathan PS, Senanayake N. Isolated bilateral laryngeal nerve 
paralysis: a delayed complication of organophosphorus poisoning. Hum Exp Toxicol 
1994;13:171-L3. 
 
38. Ernest K, Thoma M, Poulose M, Rupa V, Gnanamuthu C. Delayed effects of 
exposure to organophosphorus compounds. Ind J Med Res 1995;101:81-4. 
 
39.  Chuang FR, Jang SW, Lin JL, Chern MS, Chen JB, Hu KT. QTc prolongation 
indicates a poor prognosis in patients with organophosphorus poisoning. Am J Emerg 
Med 1996;14:451-3.   
      
40. Martin Rubi JC, Yelamus RF, Laynex BF, et al . Poisoning caused by 
organophosphate insecticides; study of 506 cases (abstract). Rev Clin Exp 
1996;196:145-9.        
 
41. Meller D, Fraser I, Kryger M. Hyperglycaemia in anticholinesterase poisoning. Can 
Med Assoc J 1981;124:745-8.      
 
42. Worek F, Backer M, Thiermann H, et al. Reappraisal of indications and limitations of 
oxime therapy in organophosphate poisoning. Hum Exp Toxicol 1997;16:466-72.        
 
43. Worek F, Diepold C, Eyer P. Dimethylphodphoryl-inhibited human cholinesterase: 
inhibition, reactivation and aging kinetics. Arch Toxicol 1999;73:7-14. 
 
 
 
44. Worek F, Eyer P, Szinicz L. Inhibition, reactivation and aging kinetics .of 
cyclohexylmethylphosphonoflouridate-inhibited cholinesterase. Arch Toxicol 
1998;72:580. 
 
45. Kenneth. D. Katz DanieEbrooks, march 16th, 2010, E medicine Toxicol.  
 
46. Bouvier G, Seta N, Vigouroux-Villard A, Blanchard O, Momas I. Insecticide urinary 
metabolites in nonoccupationally exposed populations. J Toxicol Environ Health B 
Crit Rev. Nov-Dec 2005;8(6):485-512.  
 
47. Abdel Rasoul GM, Abou Salem ME, Mechael AA, Hendy OM, Rohlman DS, Ismail 
AA. Effects of occupational pesticide exposure on children applying 
pesticides. Neurotoxicology. Sep 2008;29(5):833-8.  
 
48 wadiaRS, ShindeSN vadhya.S. Delayed neurotoxicity after an episode of poisoning 
with dichlorvos. Neurolindia 1985;247-53   
 
49.  Liu JH, Chou CY, Liu YL, et al. Acid-base interpretation can be the predictor of 
outcome among patients with acute organophosphate poisoning before 
hospitalization. Am J Emerg Med. Jan 2008;26(1):24-30.  
 
50. .C hatterjee.MSharmaPS Unusual neurological complication in a case of opc 
poisoning Neurol India 2003 5-12 90-91s 
 
 
 	
 
 
51.  Yajnesh Kidiyoor MBBS, Vinod C. Nayak MDb, etal Journal of Forensic and      egal 
Medicine Volume 16, Issue 8, November 2009, Pages 472-474. 
 
52. Dr. N. Krupesh, Dr. T.R. Chandrasekar etal, Indian journal of anesthasia, 2002 
46(1),40-43 
 

 
 
	




	
	

 


 
PROFORMA 
GENERAL: 
NAME:      AGE:  GENDER: 
MRD NO:      UNIT: 
DOA:       TIME: 
BRIEF PRESENT ILLNESS:
Date and time of  poisoning  : 
Time elapsed since ingestion of poison   :
	
 
 
PAST HISTORY: 
[     ] DM Duration:_____________ 
[     ] HT Duration:_____________  
History of previous poisoning   : 
Other relevant past history: 
 
 
 
PERSONAL HISTORY: 
 
[     ] Smoking  Duration:_____________ Quantity:_____________ 
[     ] Alcoholism Duration:_____________ Quantity:_____________ 
 
 
 
PHYSICAL EXAMINATION: 
GENERAL EXAMINATION: 
 
MEASUREMENTS: 
Height  :………. cm 
Weight :………. Kg 
BMI  :………. kg/m2 
 
VITALS: 
PR:               / min 
 [     ] Bradycardia {<60}  
 [     ] Tachycardia {>100} 
TEMP:  
 [     ] < 980 F 
 [     ] 98-990 F 
[     ] > 990 F 
RR:               / min  
[     ] < 20 
[     ] 20 – 30 
[     ] > 30 
BP:               /            mmHg  
[     ] Hypotension {<90/60} 
[     ] Normotension {90-120/60-80}   
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SYSTEMIC EXAMINATION: 
CVS: 
 
RS: 
 
ABDOMEN: 
 
CNS: 
 
INVESTIGATIONS 
INVESTIGATIONS  UNDER  STUDY: 
ECG    -   Rate                                          ECHO                CPK - MB                                           
               Rhythem 
                Axis 
               P Wave 
               PR interval 
              QRS duration 
              ST segment 
             T  Wave 
            U Wave 
           Comments: 
OTHER INVESTIGATIONS: 
TC   : 
DC   : 
ESR (1hr)  : 
HB   : 
PCV   : 
Platelets  : 
Blood Urea  : 
Sr. Creatinine  : 
Sr. Sodium  : 
Sr. Potassium  : 
Total Bilirubin : 
AST   : 
ALT   : 
SAP   : 
Total Protein  : 
 
Total Cholesterol : 
TGL   : 
LDL   : 
 
CPK   : 
CPK MB  : 
Trop T   : 
Trop I   : 
 
 : 
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IMAGING 
 
 
 CHEST XRAY : 
 
 
 ECHO   : 
 
 
TREATMENT 
 
 
 
 
 
 
  OTHER REMARKS 
Day 1 
 
 
  
Day 2 
 
 
  
Day 3 
 
 
  
Day 4 
 
 
  
Day 5 
 
 
  
Day 6 
 
 
  
Day 7 
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FOLLOW UP 
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